Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: Preclinical and early clinical data

Hematology/Oncology Clinics of North America

Volumn 18, Issue 1, 2004, Pages 41-53

  Reboul, François L ^a  

^a INSTITUT SAINTE CATHERINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; MITOMYCIN; NAVELBINE; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; ESOPHAGITIS; ESOPHAGUS DISEASE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; PATHOLOGY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; THORACOTOMY; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 1042287100     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00138-2     Document Type: Review

References (44)

1. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., Pajak T.F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8(9):1990;1543-1555.
2. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 350(9072):1997;161-165.
3. Sause W., Kolesar P., Taylor S.I., Johnson D., Livingston R., Komaki R. et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 117(2):2000;358-364.
4. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M.et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 83(6):1991;417-423.
5. Kubota K., Furuse K., Kawahara M., Kodama N., Yamamoto M., Ogawara M.et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol. 12(8):1994;1547-1552.
6. Dillman R.O., Seagren S.L., Propert K.J., Guerra J., Eaton W.L., Perry M.C.et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 323(14):1990;940-945.
7. Zak M., Drobnik J. Effect of cis-dichlorodiamine platinum (II) on the post-irradiation lethality in mice after irradiation with X-rays. Strahlentherapie. 142(1):1971;112-115.
8. Richmond R.C., Powers E.L. Radiation sensitization of bacterial spores by cis-dichlorodiamineplatinum (II). Radiat Res. 68(2):1976;251-257.
9. Douple E.B., Richmond R.C. Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiaminelatinum (II). Int J Radiat Oncol Biol Phys. 5(8):1979;1369-1372.
10. Douple E.B., Richmond R.C. A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys. 5(8):1979;1335-1339.
11. Nias A.H. Radiation and platinum drug interaction. Int J Radiat Biol Relat Stud Phys Chem Med. 48(3):1985;297-314.
12. Begg A.C. Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys. 19(5):1990;1183-1189.
13. Douple E.B. Platinum-radiation interactions. NCI Monogr. 6:1988;315-319.
14. Dewit L. Combined treatment of radiation and cis- diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 13(3):1987;403-426.
15. Fu K.K., Rayner P.A., Lam K.N. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys. 10(8):1984;1473-1478.
16. Reboul F., Vincent P., Chauvet B., Brewer Y., Felix-Faure C., Taulelle M.et al. Radiation therapy with concomitant continuous infusion cisplatin for unresectable nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys. 28(5):1994;1251-1256.
17. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P.et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 326(8):1992;524-530.
18. Soresi E., Clerici M., Grilli R., Borghini U., Zucali R., Leoni M.et al. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol. 15(6 Suppl 7):1988;20-25.
19. Trovo M.G., Minatel E., Franchin G., Boccieri M.G., Nascimben O., Bolzicco G.et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 24(1):1992;11-15.
20. Douple E.B., Richmond R.C., O'Hara J.A., Coughlin C.T. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev. 12(Suppl A):1985;111-124.
21. Yang L.X., Douple E.B., Wang H.J. Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys. 33(3):1995;641-646.
22. Ball D., Bishop J., Smith J., O'Brien P., Davis S., Ryan G.et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 52(2):1999;129-136.
23. Clamon G., Herndon J., Cooper R., Chang A.Y., Rosenman J., Green M.R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 17(1):1999;4-11.
24. Giocanti N., Hennequin C., Balosso J., Mahler M., Favaudon V. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res. 53(9):1993;2105-2111.
25. Minehan K.J., Bonner J.A. The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment. Life Sci. 53(15):1993;PL237-PL242.
26. Durand R.E., Goldie J.H. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep. 71(7-8):1987;673-679.
27. Friess G.G., Baikadi M., Harvey W.H. Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer. Cancer Treat Rep. 71(7-8):1987;681-684.
28. Reboul F., Brewer Y., Vincent P., Chauvet B., Faure C.F., Taulelle M. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys. 35(2):1996;343-350.
29. Reboul F., Chauvin G., Vincent P., Brewer Y., Felix-Faure C., Taulelle M. Preoperative radio-chemotherapy of stage III unresectable non-small cell lung cancer: results of a pilot study. Bull Cancer. 83(4):1996;300-306.
30. Reboul F. Traitements combinés préopératoires dans les cancers bronchiques non à petites cellules, in Oncologie Thoracique: synthèse des connaissances et perspectives. Groupe d'Oncologie de Langue Française. 2002;Margaux Orange, Rouen, France.
31. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi A.T. III, Weick J.K.et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 13(8):1995;1880-1892.
32. Rusch V.W., Giroux D.J., Kraut M.J., Crowley J., Hazuka M., Johnson D.et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 121(3):2001;472-483.
33. Albain K.S., Crowley J.J., Turrisi A.T. III, Gandara D.R., Farrar W.B., Clark J.I.et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 20(16):2002;3454-3460.
34. Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 13(2):1995;452-458.
35. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 14(4):1996;1065-1070.
36. Jeremic B., Shibamoto Y., Milicic B., Nikolic N., Dagovic A., Milisavljevic S. Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study. Int J Radiat Oncol Biol Phys. 42(5):1998;1091-1096.
37. Jeremic B., Shibamoto Y., Milicic B., Milisavljevic S., Nikolic N., Dagovic A.et al. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 44(2):1999;343-348.
38. Lee J.S., Scott C., Komaki R., Fossella F.V., Dundas G.S., McDonald S.et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol. 14(4):1996;1055-1064.
39. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H.et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol. 16(2):1998;622-634.
40. Liao Z., Komaki R., Stevens C., Kelly J., Fossella F., Lee J.S.et al. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 53(3):2002;558-565.
41. Schild S.E., Stella P.J., Geyer S.M., Bonner J.A., Marks R.S., McGinnis W.L.et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 54(2):2002;370-378.
42. Komaki R., Seiferheld W., Ettinger D., Lee J.S., Movsas B., Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys. 53(3):2002;548-557.
43. Curran W.J., Scott C., Langer C., Komaki R., Lee J.S., Hauser S., et al. Phase III comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Presented at the 36th annual meeting of the American Society of Clinical Oncology 2000;19:484a.
44. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17(9):1999;2692-2699.